RxDoctor Payments Data

Christiana Olayera-Akinboye, NP

Psychiatric/Mental Health · Baltimore, MDNPI 1235882903

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 22.1% of the total. 2025 is the largest year on record at $203, more than ten times the $15 reported in 2022. That places this record below the midpoint for psychiatric/mental health clinicians in MD, where the typical reported total is $349.

$410in general payments, 2019–2025

Across 19 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$91
  • AbbVie$82
  • Indivior Inc.$80
  • Neurocrine Biosciences, Inc.$56
  • Lundbeck LLC$53
  • Alkermes, Inc.$25
  • plus $24 from 1 others

What the payments were for

  • Food & beverage$410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$410 in reported general payments places this provider in the 50th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland →

Medicare billing

Part B allowed, 2024
$26,473
Medicare patients
21
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate16$58,656
Lurasidone Hcl20$4,764
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl61$4,023
Divalproex Sodium ErDivalproex Sodium14$1,200
Olanzapine15$906
Venlafaxine Hcl ErVenlafaxine Hcl13$811
Clonazepam59$618
Quetiapine Fumarate32$520
Trazodone Hcl57$454
Bupropion XlBupropion Hcl17$394
Oxcarbazepine14$383
Buspirone Hcl41$307
Gabapentin12$294
Sertraline Hcl28$262
Doxepin Hcl11$259

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Baltimore

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →